uniQure N.V.
QURE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.78B
Close$
$-8.57
128.7% downside
Current Fair Value
128.7% downsideOvervalued by 128.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.78 Billion |
|---|---|
| Enterprise Value | $1.71 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.46 |
| Beta | 0.87 |
| Outstanding Shares | 62,742,847 |
Return
| Return on Equity | -139.86% |
|---|---|
| Return on Assets | -26.82% |
| Return on Invested Capital | -32.82% |
Valuation & Multiples
| P/E Ratio | -8.57 |
|---|---|
| PEG | -37.78 |
| Price to Sales | - |
| Price to Book Ratio | 14.94 |
| Enterprise Value to Revenue | 94.36 |
| Enterprise Value to EBIT | -7.23 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$5.24 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.84
Average shareholder expectationRevenue Estimate
$5.37 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1482▼ 12.81% |
|---|---|
| Total Calls | 14,277,940▲ 99.64% |
| Total Puts | 2,115,288▲ 7.05% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 103.63%▼ 2.08% |
|---|---|
| Total Invested | $969.57M▼ 34.51% |
| Investors Holding | 257▼ 4.00% |
ESG Score
No data
About uniQure N.V.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...